Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Medicare Revamps Competitive Bidding Program
The Centers for Medicare & Medicaid Services is preparing to revive competitive bidding program for durable medical equipment that industry members helped sink last summer when it was originally scheduled to take effect, CQ HealthBeat reports. The agency had anticipated a 26 percent savings for wheelchairs, oxygen tanks and other pieces of equipment through the program. But a lobbying group for the suppliers, the American Association for Homecare, successfully urged Congress to shut down the program before it went into effect.
generic viagra online
RCN Calls For EU Agreement On Sharps Injuries To Be Implemented Quickly
The Royal College of Nursing welcomed the signing of a joint agreement by European Federation of Public Service Unions (EPSU) and the European Hospital and Healthcare Employers Association (HOSPEEM). This is an EU-wide agreement which the RCN has played a key role in bringing about to prevent one million medical sharps injuries per year. Dr Peter Carter, Chief Executive of the Royal College of Nursing (RCN), said:
News of the day
IOM Comparative Effectiveness Research Priorities Report
A new report from the Institute of Medicine recommends 100 health topics that should get priority attention and funding from a new national research effort to identify which health care services work best. It also spells out actions and res needed to ensure that this comparative effectiveness research initiative will be a sustained effort with a continuous process for updating priorities as needed and that the results are put into clinical practice.
Public Health

Bayer Schering Pharma Announces New Data On Novel Anti-cancer Compound BAY 73-4506

Bayer Schering Pharma AG announced results from Phase I and II trials of BAY 73-4506, a potent oral multi-kinase inhibitor currently being studied in multiple tumor types. These data were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). "Bayer is committed to discovering new cancer-fighting therapies," said Kemal Malik, MD, member of the Board of Management and Head of Global Development at Bayer Schering Pharma AG. "We are encouraged by these Phase I and II data being presented on BAY 73-4506. These data will help further determine our next steps as we move forward with a comprehensive Phase III clinical development program in various tumor types for this new drug candidate." Preliminary data from the Phase II, open-label study in renal cell carcinoma (RCC) demonstrated a 27 percent partial response (PR) rate according to the Response Evaluation Criteria in Solid Tumors (RECIST) and a disease control rate of 79 percent. The most common drug-related adverse events were hand-foot skin reaction, fatigue, hypertension, mucositis, dysphonia, rash, diarrhea, and anorexia. The Phase II study enrolled 49 previously untreated patients with predominantly clear cell RCC. BAY 73-4506 (160 mg) was administered once daily on a three weeks on/one week off schedule. The primary endpoint was to evaluate response rate according to RECIST. "We are encouraged by these data of BAY 73-4506," said lead investigator Professor Tim Eisen, F.R.C.P., PhD, of Addenbrooke"s Hospital at the University of Cambridge, UK. "These data provide a rationale to move into a Phase III trial in one of the multiple tumor types that may be responsive to BAY 73-4506." Additional data presented on BAY 73-4506 include a Phase I study of patients with advanced refractory colorectal carcinoma (CRC). The data were presented by lead investigator Dirk Strumberg, MD, Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Germany. Data from the Phase I dose-finding study in CRC showed BAY 73-4506, dosed at 160 mg daily, using a treatment schedule of 21 days on/7 days off, was feasible in patients with advanced refractory CRC. Disease control rate (PR + SD) was 74 percent in evaluable patients. The most common drug-related adverse events were hand-foot skin reaction, fatigue, hoarseness, mucositis, diarrhea, anorexia and hypertension. Data presented are based on 38 patients with actively progressing CRC enrolled in a Phase I study. Patients were treated with BAY 73-4506 at doses of 60 mg, 120 mg, 160 mg, and 220 mg once daily. About BAY 73-4506 (DAST-Inhibitor) BAY 73-4506 is a dual targeted VEGFR2-TIE2 anti-angiogenic oral tyrosine kinase inhibitor (TKI) with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). In preclinical studies, BAY 73-4506 has been shown to inhibit tumor growth by hitting targets along a spectrum of angiogenic pathways, including VEGFR and TIE2. BAY 73-4506 has also been shown in preclinical studies to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The clinical significance of these studies is not known and warrant further investigation in a broad spectrum of tumors. Bayer Schering Pharma AG


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009